Anavex Life Sciences Corp (AVXL)

[nidan7500]

A PET scan will show Sigma-1 A2-73 occupancy and the full genomic profile combined with other factors will reveal the relationship between the two to provide the inclusion criteria for trials in likely high responders.

Absolutely agree. He has chosen these topics/titles for a very good reason, they are complimentary and show solid science w/o arm waving.

We need precision science to rule the AAIC day. No more crap shoot-shot gunning trials that stretch beyond the horizon and accomplish nothing. He should be able to present with a confidence level approaching certainty that full genomic profiles link with certain AD restoration and regeneration profiles. Supporting PET is a killer.

I also expect he will be given "late breaking" status and will be representing A2-73 results in that context in addition to posters.

We just learned of another close friend being diagnosed with AD. These people have had their lives turned upside down with uncertainty. The need could not be greater.